Herbex-kid Inhibits Immediate Hypersensitivity Reactions in Mice and Rats by Kumar, Anil et al.
Advance Access Publication 17 May 2007 eCAM 2008;5(3)289–294
doi:10.1093/ecam/nem034
Original Article
Herbex-kid Inhibits Immediate Hypersensitivity Reactions
in Mice and Rats
Anil Kumar
1, Rawal Prasad
1, Nanjan Mulla Jogge
2, Suresh Bhojraj





2TIFAC CORE in Herbal Drugs, JSS College of Pharmacy, Ootacamund 643001
and
3Green Milk Concepts, Herbal Division of Apex Laboratories, Chennai 600038, India
Herbex-kid (HK), a polyherbal formulation was evaluated in various experimental allergic
models of Type I hypersensitivity reactions. Compound 48/80 (C 48/80) has been shown to
induce rat mesentery mast cell degranulation and HK (1.07, 10.75 and 107.5mgml
 1) inhibited
the mast cell degranulation in a dose dependent manner. HK (1.07, 10.75 and 107.5mgkg
 1;
p.o.) showed dose-dependent protection against C 48/80 induced systemic anaphylaxis in male
Balb/C mice. In active anaphylaxis model, male Wistar rats orally administered with 10.75 and
107.5mgkg
 1 of HK showed significant (P50.01) protection against mast cell degranulation,
while in passive anaphylaxis model, only at 107.5mgkg
 1 showed significant (P50.01)
reduction in mast cell degranulation. HK at all dose levels was able to significantly decrease the
time spent in nasal rubbing in Wistar rats sensitized to ovalbumin, while only at 107.5mgkg
 1
it showed significant (P50.01) reduction in number of sneezes. In C 48/80-induced skin itch
model, all dose levels of HK significantly (P50.001) decreased the time spent in itching and the
number of itches. HK did not produce any significant inhibition in histamine induced
contraction in guinea pig ileum. From the above findings we conclude that the HK possesses
antiallergic activity mediated by reducing of the release mediators from mast cells and also by
5-HT antagonism without the involvement of histamine (H1) receptors.
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Introduction
Herbex-kid (HK) a polyherbal syrup developed and
marketed by Apex Laboratories Ltd, India, contains
herbal extracts standardized by HPTLC method.
Each 5ml of the syrup contains extracts of Abies webbiana
(75mg), Alpinia chinensis (150mg), Baleria perionitis
(75mg), Bacopa monniera (75mg), Bryonia scabrilla
(100mg), Coleus aromaticus (100mg), Ocimum sanctum
(200mg), Piper longum (100mg) and Solanum trilobatum
(200mg). All these herbs are traditionally in India for
treating various allergic disorders such as cough, asthma,
colds,purititisandotherinflammatorydiseases(1).Someof
these herbs used in the formulation such as A. chinensis, O.
santum and P. longum have been evaluated for their
immunomodulatory (2–6), antitussive (7), anti-inflamma-
toryproperties(6,8,9).Type I or immediate hypersensitivity
reaction consists of various allergic disorders, ranging form
serious anaphylactic reaction to acute pruritus reaction and
chronic conditions like allergic asthma. The basic compo-
nents involved in the Type I allergic reaction are the mast
cells and IgE antibodies (10). Complimentary alternative
medicine (CAM) has been shown to be effective andworthy
against several allergic disorders, where as conventional
treatment has not shown to be effective including in cases
of atopic dermatitis (11–15). Recently, evidence-based
research, in CAM has been directed at best for establishing
therapeutic evidence in CAM by stringent research, thereby
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properly cited.integrating CAM into Western medicine. A need, therefore,
has arisen to validate the claims of herbal medicine (16,17).
Hence the present study was taken up to evaluate the
formula in different animal models to assess Type I
reactions involving mast cells.
Methods
Experimental Rats and Mice
Male Wistar rats (200–220g), male Balb/C mice (18–22g)
and guinea pig (350–500g) of either sex were obtained from
the Central Animal House Facility of JSS College of
Pharmacy, Ootacamund. They were maintained under
controlled conditions at temperature of 22 2 C, humidity
60 10% and a 12/12 light/dark cycle. They had free access
to standard rodent pellet and water. All experimental
protocols were approved bythe Institutional Animal Ethics
Committee prior to beginning the experiments.
Drugs and Chemicals
Compound 48/80 (C 48/80), histamine acid phosphate
and ovalbumin (OVA) were purchased from Sigma
Chemicals Co., USA, horse serum from Hi-Media,
India, o-Toludine blue and other solvents from S.D.
Fine Chemicals, India, cetrizine hydrochloride, cyprohep-
tadine and predinisolone as gift samples from Tablets
(India) Pvt. Ltd, disodium cromoglycate (DSCG) from
Cipla, India, triple antigen from Serum Institute of India
and Herbex-kid syrup (HK) was a generous gift from
Apex Laboratories, Chennai, India.
Mast Cell Stabilization Activity
The overnight fasted male Wistar rats were sacrificed
with excess dose of anesthetic ether and the abdomen was
cut open to expose the intestine. Pieces of mesentery with
connecting lobes of fat and blood vessels were rapidly
dissected out and cut into small pieces and placed in a
beaker containing Ringer Locke (mM concentrations of
NaCl 154, KCl 5.6, CaCl2 2.2, NaHCO3 6.0 and dextrose
5.5) solution for 30 1min. Different dilutions of HK
(1.07, 10.7 and 107.5mgml
 1) were prepared in Ringer
Locke solution. Then the tissues were incubated with C
48/80 (0.8mgml
 1) for a period of 30 1min. The pieces
of mesentery were then placed on a clean slide. Excess
fatty layers and adhering tissues were carefully removed.
The trimmed tissue was placed in 4% formaldehyde
solution containing 0.1% o-Toludine blue for 20–30min
and the tissue was then de-stained with acetone and
xylene (two changes each) for 5 1min. The stained
mesentery pieces were examined under a digital light
microscope (M/s. Motic, Japan) at 100  magnification
and 100 mast cells were counted, starting from the left
hand side of the field and then proceeding clockwise. The
number of intact, fragmented or disrupted mast cells were
counted. A mast cell was considered disrupted if four or
five granules were observed around the mast cells (18).
The percentage of fragmented or disrupted and intact
mast cells was calculated. Six pieces of mesentery were
used for each concentration of the test sample.
Systemic Anaphylaxis Model in Mice
The overnight fasted male Balb/C mice were administered
orally with various doses of HK (1.07, 10.75 and
107.5mgkg
 1) and after 1h, 8mgkg
 1 of C 48/80 dissolved
in normal saline was administered i.p. into each animal.
Mice were placed in an observation cage (30 30cm) made
of perplex glass 10min before the injection of C 48/80, for
acclimatization andafterinjection theywereputbackinthe
observation cage (one mouse per cage) and the death time
(in min) was noted (19).
Active Anaphylaxis Model using Rat Mesentery
Male Wistar rats were weighed and randomly selected.
All rats were given 0.5ml of horse serum along with
0.5ml of triple antigen containing 20000 million
Bordetella pertusis organisms by subcutaneous route
(20). Later rats were orally administered with HK (1.07,
10.75 and 107.5mgkg
 1) or prednisolone acetate
(10mgkg
 1) once daily for 14 days. They were sacrificed
on day 14, 1h after the administration of the test
substance. The abdomen was cut open to expose the
intestine. Pieces of mesentery with connecting lobes of fat
and blood vessels were rapidly dissected out and cut into
small pieces and placed in a beaker containing 5ml of
Ringer Locke solution for 30 1min. The mesenteric
pieces were then shifted to a beaker containing 5% v/v
horse serum diluted in Ringer Locke solution. After an
incubation period of 10min, the tissues were removed,
trimmed and stained with 0.1% o-Toludine solution and
placed on a microscopic slide and the numbers of intact
and fragmented/disrupted mast cells were counted under
a digital microscope. From each rat, three mesenteric
tissues were used for counting mast cells and the average
from three observations were used to calculate the
percentage of mast cells disrupted/fragmented and intact
cells.
Passive Anaphylactic Model using Rat Mesentery
The vehicle control rats in the active anaphylactic model,
used in the previous experiment were used for the study.
On day 14, before sacrificing them, blood was withdrawn
from each animal by sino-orbital puncture and serum
separated aseptically. The serum thus obtained was
administered (1ml per rat; i.p.) to selected animals of
all groups. After 1h, HK (1.07, 10.75 and 107.5mgkg
 1)
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and on the following day as well. Forty-eight hours after
the administration of rat serum, animals were challenged
with 1ml of horse serum by i.p. injection (20).
Ten minutes later were sacrificed and the intestinal
mesentery was collected and incubated in Ringer Locke
solution for 30min. Later pieces of mesentery were
placed on slide and stained with 0.1% o-Toludine blue
and the number of intact and disrupted mast cells were
counted from each tissue. From each animal, three
mesenteric tissue pieces were used for counting
mast cells and the average of three observations
were taken for calculating the percentage.
Nasal Allergy Model in Sensitized Rats
Male Wistar rats were weighed and randomly selected.
The animals were injected intraperitoneally with 1mg of
OVA and 10mg of alum prepared in 1ml of normal
saline for 7 days (21). On day 14, the overnight fasted
were orally administered with HK (1.07, 10.75 and
107.5mgkg
 1) or cetrizine (1mgkg
 1). After 1h, animals
were sensitized locally with OVA in saline solution
(10mg10ml
 1 per nostril). This was carried out by
dropping OVA solution into the bilateral nasal cavities
by a micropippete. Ten minutes before instilling OVA
into the nostrils, rats were placed in an observation cage
(30 30cm), made of perplex glass, for acclimatization
then placed back into the observation cage (one rat per
cage) and the number of sneezes and the nasal rubbing
were counted for 30min by a trained observer unaware of
the treatment given earlier.
Skin Itch Induced by C 48/80 in Mice
Male Balb/C mice numbering 36 were divided into
six groups with six in each group. Itching or scratching
was induced in them by intradermal injection of 20ml
containing 100mg of C 48/80 (dissolved in normal saline)
on the rostral part of the back of shaved skin (22).
Ten minutes before the injection, each mouse was
placed in the observation chamber (30 30cm) made of
perplex glass. The number of scratches and the time spent
in scratching was visually noted for 60min. Scratching
behavior was characterized by vigorous scratching of the
injected area with the hind limb.
Histamine Induced Contraction in Guinea Pig Ileum
Guinea pigs of either sex were starved overnight with free
access to water. A segment of the ileum (2-cm-long) was
suspended in a 30ml organ bath containing Tyrode’s
solution (mM concentration of NaCl 136.9, Glucose 5.6,
NaHCO3 11.9, KCl 2.68, MgSO4 1.05, CaCl2 1.8,
NaH2PO4 0.37), gassed with air and maintained
at 37 C. The tissue was allowed to equilibrate for
45min and the Tyrode’s solution was replaced every
15min intervals. Dose response curves were obtained
for histamine acid phosphate at various concentrations.
Later the Tyrode solution was replaced by HK
prepared in Tyrode solution containing various concen-
trations (0.1, 1 and 10% v/v) and the contractile
response of the ileum was obtained in the presence of
histamine. Contact time between the agonist and
the tissue was between 30 and 45s. Experiments
were carried out in triplicate (n¼3). The IC50 was
calculated for histamine, in the presence and absence
of HK, at various concentrations (23).
Statistical Analysis
Results were expressed as mean SEM. The intergroup
variation was compared statistically using One way
Analysis of Variance (ANOVA) followed by Dunnett’s
multiple comparison test or with Tukey’s multiple
comparison test wherever applicable. Statistical signifi-
cance was considered at P50.05. The analysis was
carried out using GraphPad Prism software V.4.
Results
HK Stabilizes Mast Cell Degranulation Induced by C
48/80
C48/80, a known mast cell degranulating agent, produced
a significant (P50.001) increase in degranulation in
rat mesenteric mast cells (92.7 1.3), when compared
with the mesentery exposed to Ringer Locke’s solution
alone (18.5 3.4). The C 48/80 treated mesentry
when exposed to HK produced a dose dependent
reduction in the number of degranulated mast cells.
HK at 1.07mgml
 1 showed 74.0 3.5 number
of degranulated mast cells per 100 mast cells counted,
while 10.75 and 107.5mgml
 1 showed significant
reduction (P50.01) in the number of degranulated
mast cells namely, 25.2 4.6 and 10.7 3.9, in the
presence of 0.8mgml
 1C 48/80. Disodium cromoglycate
(1mgml
 1), a known mast cell-stabilizing agent
also brought significant (P50.01) reduction in degranu-
lated mast cells (Fig. 1).
Survival Time Improved in Systemic Anaphylaxis Model
In vehicle treated mice, systemic anaphylaxis was
observed within 19.3 1.5min. Oral pre-treatment with
HK, 1h before the administration of C 48/80, showed
a dose-dependent increase in latency to death time.
Only HK at 107.5mgkg
 1 produced significant increase
(P50.01) in latency to death time, namely, 49.5 9.6min
when compared with controls (Fig. 2).
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Fourteen days of treatment with HK to presensitized rats
produced dose dependent reduction in the degranulation
of mast cell. HK at both 10.75, 107.5mgkg
 1 prod-
uced significant increase (P50.01) in the number of
intact mast cells, namely, 58.9 3.7 and 68.1 2.8,
when compared with vehicle control upon exposure
to 0.5% horse serum, 30.1 4.4. Prednisolone
(10mgkg
 1), used as a positive control also produced
significant (P50.01) increase in intact mast cells,
73.6 3.5 (Fig. 3).
Only HK at High Dose Increased the Number of Intact
Mast Cells
In passive anaphylaxis model, only HK at 107.5mgkg
 1
produced significant (P50.01) increase in the number
of intact mast cells, 64.2 2.7 when compared with
control namely 40.8 4.5, while at all other doses,
HK did not produce significant increase in the number
of intact mast cells when compared with vehicle
control (Fig. 3).
Nasal Rubbing Suppressed after Induction by OVA
The vehicle treated OVA sensitized mice, produced
17.3 2.8 number of sneezes and the time spent in
nasal rubbing was 245.3 10.7s. The onset of sneezing
was at 156.5 48.3s. Pre-treatment of HK to OVA
sensitized Balb/C mice produced dose–dependent reduc-
tion in the number of sneezes and time spent in nasal
rubbing. At all dose levels, HK produced significant
reduction (P50.01) in time spent in nasal rubbing. HK
at 1.07mgkg
 1 showed 184.3 16.6s (P50.05) of nasal
rubbing while 10.75 and 107.5mgkg
 1 treated animals
showed significant reduction (P50.01) in the time spent
in nasal rubbing, namely, 160.5 10.3s, 84.7 15.5s.
Only HK at 107.5mgkg
 1 showed significant reduction
(P50.01) in number of sneezing, 4.5 0.8, when com-
pared with control. Moreover, both the standard drug,
cetrizine and the herbal formulation, HK, however, did
not produce any significant changes in onset of sneezing
(Table 1).
Itching Induced by C 48/80 Reduced
In vehicle treated mice, intradermal injection of 20mlo f
100mg of C 48/80 produced significant (P50.001)
increase in the number of itches (181.7 14.1) and the
time spent in itching (267.7 18.7s) when compared with
the vehicle treated mice injected with 20ml of normal
saline intradermally, namely, 13.0 6.0s and 6.2 3.2s.
Pre-treatment with HK produced dose-dependent reduc-
tion in both these parameters. HK at 1.07mgkg
 1
showed non-significant reduction in the numbers of
itches (135.7 4.4) and significantly (P50.001) reduced
the time spent in itching, namely, 165.3 4.4s when
compared with C48/80 control. HK at 10.75 and
107.5mgkg
 1 produced significant reduction (P50.01)
in time spent in itching, namely, 146.2 8.4 and
Figure 1. Effect of Herbex-kid (HK) on mast cell degranulation
induced by C 48/80 in rat mesentery tissue. Values are mean SEM.
Number of tissues per group is six.
*aP50.001 vs control;
*bP50.001 vs
C 48/80; One way ANOVA followed by Tukey’s multiple comparison
test. DSSG: disodium cromoglycate; C 48/80: Compound 48/80.
Figure 2. Effect of Herbex-kid (HK) in C 48/80 induced systemic
anaphylaxis in Balb/C mice. Each bar represents mean SEM of six
mice each.
**P50.01 vs control. One way ANOVA followed by
Dunnett’s multiple comparison test. C 48/80: Compound 48/80.
Figure 3. Effect of Herbex-kid (HK) in active (plain bars) and passive
anaphylaxis (shaded bars) model in rats. Each bar represents
mean SEM of six rats each.
*P50.05,
**P50.01 vs the experiment
respective controls; One way ANOVA followed by Dunnett’s multiple
comparison test. Pred: Prednisolone (10mgkg
 1).
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the number of skin itches, namely, 124.5 3.6 and
118.0 20.6, when compared with C 48/80 control.
The standard cyproheptadine at 1mgkg
 1 also showed
significant reduction in the number of itches (P50.05)
and time spent in itching (P50.001) induced by C48/80
(Fig. 4).
Non-Antagonism of Histamine
HK at concentrations of 0.1, 1 and 10% did not have any
effect on histamine induced guinea pig ileum contraction
(data not shown).
Discussion
Allergies are one of the common disorders affecting
mankind. The basic components involved in Type I
hypersensitivity allergic reactions are the mast cells and
IgE antibodies (10). Presently most of the antiallergic
agents are of H1-antagonist (24). Recently rupatadine
dual histamine (H1) and platelet activated factor (PAF)
has been developed (25). It is becoming clear that
antihistaminics alone do not provide the full therapeutic
value for most of the Type I allergic reaction (26).
From the histamine induced guinea pig ileum contrac-
tion, we conclude that HK does not possess prominent
antihistaminic properties. Degranulation of mast cells,
causes release of pre-formed and newly formed mediators
leading to acute and late phase allergic reactions
depending on the allergic disease (24). From the present
study, HK possesses significant mast cell stabilization
activity. Nevertheless certain types of allergic reactions
like perennial rhinitis, atopic dermatitis and even in
allergic asthma, several immune cells along with inflam-
matory mediators play an important role. By active and
passive anaphylaxis model, it has been established that
HK possess a certain degree of immunological property,
which may be due to the herbs such as O. sanctum or A.
chinensis which possess immunomodulatory properties
(3,4).
Allergic rhinitis is a very common condition, character-
ized by early and late phase immune response (27).
Antihistamines are commonly used for the relief of
allergic rhinitis which may be beneficial in relieving
sneezing but not other symptoms of allergic rhinitis (26).
In the present study, OVA sensitized rat animal model
of nasal allergy was used, as this model closely
corresponds to the allergic rhinitis in humans, involving
both early and late phase of immune response (28).
In the early phase, the principal component is mast cell
and histamine and is characterized by sneezing, and the
late phase is characterized by nasal rubbing, wherein
other inflammatory components are involved (21).
The OVA model for nasal allergy involves both these
phases. HK significantly reduced the time spent in nasal
rubbing (late phase) at all the three dose level employed,
but only at high dose the number of sneezes (early phase)
was reduced significantly. Based on these observations,
HK’s involvement with the immunological component
along with mast cell stabilization property would be
the major feature in attenuating the allergic response
without the involvement of histamine receptors.
Based on the above fact, C48/80 induced itch model in
mice, was, therefore employed, as antihistamines do not
provide protection against C48/80-induced itching.
Itching behavior is thus independent of histamine
though mast cells are degranulated (29). Lipid mediators
Table 1. Effect of Herbex-kid in nasal allergy in antigen sensitized rats
Treatment (n¼6) Dose (mgkg
 1; p.o.) Number of sneezes Time spent in nasal rubbing (s) Onset of sneezing (s)
Control – 17.3 2.8 245.3 10.7 156.5 48.3
n-Cetrizine 10 4.7 0.9** 121.2 17.9** 97.5 19.4
Herbex-kid 1.07 14.5 3.7 184.3 16.6* 63.2 17.5
10.75 9.2 1.6 160.5 10.3** 74.3 16.1
107.5 4.5 0.8** 84.7 15.5** 245.5 58.9
Values are mean SEM; n¼number of rats per group.
*P50.05; **P50.01 vs control; One way Analysis of Variance (ANOVA) followed by Dunnett’s multiple comparison test.
Figure 4. Herbex-kid (HK) at various doses in C 48/80 (Compound 48/
80)-induced itching in Balb/C mice. Each bar represents mean of six
mice each.
***aP50.001 vs vehicle control;
*bP50.05,
***bP50.001 vs C
48/80; One way ANOVA followed by Tukey’s multiple comparison test.
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participate in induction of itching (30). From the results
of this experiment, it was evident that of all the dose level
employed, HK produced significant reduction in number
and time spent in itching, suggesting that HK has potent
antipruritic activity probably mediated by mast cell
stabilization along with 5-HT antagonism.
On the whole, the antiallergic property of HK could be
attributed to the presence of immunomodulatory herbs
such as A. chinensis (3), O. sanctum (4), P. longum (5) and
antiallergic herbs such as B. monniera (31) and P. longum
(32) used in the formulation, which further strengthens
the concept of synergistic healing potential of polyherbal
formulations (33).
In conclusion, the antiallergic property of HK could be
through the involvement of mast cell stabilization,
immunomodulatory activity and 5-HT antagonism with-
out the involvement of histamine receptors. From the
encouraging results obtained from this study, further
experiments are being conducted to evaluate the potential
of HK in experimental allergic asthmatic model and its
immunological activity.
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